This is a single arm phase II study to explore the 3y LRFS and safety for high-risk early rectal cancer after local excision with short-course radiotherapy and chemo-immunotherapy.
A total of 60 patients with high-risk pathologic stage pT1 or pT2 cancer after local excision but refused radical surgery will be included. Eligibility criteria include a histological diagnosis of adenocarcinoma located ≤7 cm from the anal verge, pT1 after local excision of the primary rectal cancer, with one of the high-risk features including margin positivity/very close margin (\<1mm) at time of local excision, depth of invasion \>1 mm or SM3 invasion (submucosal invasion to the lower third of the submucosal level), high grade or poorly differentiated, lymphovascular invasion, perineural invasion, tumour budding, or pT2 tumor. They will receive 5\*5Gy short-course radiotherapy, followed by 4 cycles of capecitabine plus oxaliplatin (CAPOX) chemotherapy and PD-1 antibody.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Shor-course radiotherapy: 25Gy/5Fx
PD-1 antibody (Toripalimab): 240mg d1 q3w
Capecitabine: 1000mg/m2 d1-14 q3w
Fudan University Shanghai Cancer Center
Shanghai, China
RECRUITING3y LRFS
Rate of 3 year local recurrence free survival rate
Time frame: From date of initiation of treatment until the date of first documented pelvic failure, assessed up to 36 months.
3y DFS
Rate of 3 year disease free survival
Time frame: From date of initiation of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.
3y OS
Rate of 3 year overall survival
Time frame: From date of initiation of treatment until the date of death from any cause, assessed up to 36 months.
Grade 3-4 adverse effects rate
Rate of chemotherapy, radiotherapy and immunotherapy related adverse events
Time frame: From date of initiation of treatment until the date of death from any cause, assessed up to 36 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Oxaliplatin: 130mg/m2 d1 q3w